Hear directly from local medical professionals as they discuss prostate cancer and treatments. Hear directly from local medical professionals as they discuss prostate cancer and treatments right here ...
An update from Radiopharm Theranostics Limited ( (AU:RAD)) is now available. Radiopharm Theranostics Limited has received approval from the Bellberry Human Research Ethics Committee in Australia to ...
Prostate cancer is the most common cancer among men, yet it remains one of the least known. Prostate carcinoma affects about ...
SYDNEY, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology ...
Ethics approval and Phase 1 clinical trial start in prostate cancer anticipated in 2H 2025 SYDNEY and BUNDOORA, Australia, June 24, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: ...
The PSMA-targeted therapy market is expected to grow strongly, fueled by higher prostate cancer diagnosis rates, improved awareness of PSMA-based treatments, and an expanding clinical trial landscape ...
MELBOURNE, Australia and PALO ALTO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces a strategic clinical collaboration with ...
News Medical on MSN
UCLA Health launches novel clinical trial for recurrent prostate cancer
The Phase 2 trial, called ANDROMEDA, is the first study to directly compare two types of PSMA-targeted radiopharmaceuticals when used alongside stereotactic body radiotherapy (SBRT), a focused form of ...
Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic body radiotherapy (SBRT) went more than twice as long without their disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback